Found 16 matching trials
Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon
PHASE2The trial is a single-centre, randomized, double-blind, parallel trial in G...
Location
Profil Institut für Stoffwechselforschung GmbH
ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon
PHASE2The trial is a single-centre, randomised, sequential, cross-over trial asse...
Location
Profil Institut für Stoffwechselforschung GmbH
Incretin and KATP Channels
NAThis study aims to examine the involvement of KATP channels on the microvas...
Location
Royal Devon and Exeter NHS Foundation Trust
The Microvascular Function of GLP-1 and Its Analogues
NAIncretins have become a successful drug target in the repertoire of medicat...
Location
Diabetes and Vascular Center
The Effect of GLP-1 on the Inhibition of Glucagon Secretion
NADiabetes(both types) are recognized by high levels of glucagon in the circu...
Location
Gentofte University Hospital
Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus
NAIncretinbased treatment of patients with type 2 diabetes mellitus (T2DM) ha...
Location
Multiple Locations
Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET
PHASE210 healthy men will be PET-scanned (CNS) twice in random order with infusio...
Location
Aarhus University, Institute of Pharmacology
A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus
PHASE3The trial's objective is to evaluate the immunogenicity of repeated single ...
GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans
PHASE1The inhibitory effect of low dose GLP-1 is investigated on prandial motilit...
Location
Uppsala University
Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a Comparator
PHASE1The trial is a randomized, double-blind First in Human trial to evaluate th...